Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6077 in Advanced Malignant Tumor
NCT07873359Phase 1Not yet recruiting
- Sponsor
- Beijing Kangchuanglian Biopharmaceutical Technology Research
- Start
- Nov 2026
- Primary completion
- Dec 2028
01
Overview
Phase 1, open-label trial of SYS6077 in solid tumor (3 arms), sponsored by Beijing Kangchuanglian Biopharmaceutical Technology Research. Primary endpoints: Adverse Events at 5 years, Serious Adverse Events at 5 years and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
SYS6077
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07873359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07873359.